04/06/2019  00:00:00 Chg. - Volume Bid16:27:31 Demandez à- Capitalisation boursière Dividende Y. Rapport P/E
6,575.00HUF - 400
Chiffrre d'affaires: -
-Bid taille: - -Ask la taille: - 1783.61 Mrd.HUF - 11.13

Description de l'entreprise

Gedeon Richter Plc., headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.
 

Conseil d'administration & Conseil de surveillance

PDG
Gabor Orban
Conseil d'administration
István Hamecz, Katalin Erdei, Dr István Greiner, Tibor Horváth, Attila Szénási, Tamás Szolyák
Conseil de surveillance
Prof Dr Szilveszter E. Vizi, Dr Ilona Hardy dr Pintérné, Erik Bogsch, Gábor Orbán, Dr Nándor Pál Ács, Gabriella Balogh, István Hamecz, Dr Péter Cserháti, Mrs Lászlóné Németh, Dr Anett Pandurics, Bálint Szécsényi, Balázs Szepesi, Dr Attila Chikán, Dr Róbert Jonathán Bedros, Dr Krisztina Gál, Dr Zoltán Matos, Dr Lívia Pavlik, Ferenc Sallai
 

Données de l'entreprise

Nom: Chemical Works of Gedeon Richter PLC
Adresse: Gyömroi út 19-21.,HU-1103 Budapest
Téléphone: +(36) 1-431-4000
Fax: +(36) 1-260-6650
Courriel: investor.relations@richter.hu
Internet: https://www.gedeonrichter.com/en/
Industrie: Healthcare
Secteur: Pharmaceutical Industry
Sous-secteur: -
Fin de l'exercice financier: 31/12
Flotte libre: 74.93%
IPO date: 09/11/1994

Relations avec les investisseurs

Nom: Katalin Ördög
Téléphone IR: +36-1-431 5764
IR-Fax: -
E-mail IR: investor.relations@richter.hu

Calendrier de l'entreprise

CW 32 | 06/08/2024 Interim Report 2nd Quarter/6 Months
CW 46 | 12/11/2024 Interim Report 3rd Quarter/9 Months